Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $93.3 million.

  • Editas Medicine's Shares Outstanding rose 1299.49% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year increase of 1299.49%. This contributed to the annual value of $82.7 million for FY2024, which is 118.32% up from last year.
  • Editas Medicine's Shares Outstanding amounted to $93.3 million in Q3 2025, which was up 1299.49% from $87.4 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Shares Outstanding ranged from a high of $93.3 million in Q3 2025 and a low of $67.5 million during Q1 2021
  • Moreover, its 5-year median value for Shares Outstanding was $81.6 million (2023), whereas its average is $76.6 million.
  • Its Shares Outstanding has fluctuated over the past 5 years, first surged by 2311.98% in 2021, then surged by 56.98% in 2023.
  • Quarter analysis of 5 years shows Editas Medicine's Shares Outstanding stood at $68.4 million in 2021, then grew by 0.6% to $68.8 million in 2022, then increased by 18.77% to $81.8 million in 2023, then increased by 1.18% to $82.7 million in 2024, then rose by 12.73% to $93.3 million in 2025.
  • Its Shares Outstanding was $93.3 million in Q3 2025, compared to $87.4 million in Q2 2025 and $83.7 million in Q1 2025.